SEC	Form	4
-----	------	---

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
Name and Address of Reporting Person*

1. Name and Address of Reporting Person [*] Baluch Khoso			2. Issuer Name and Ticker or Trading Symbol <u>Processa Pharmaceuticals, Inc.</u> [PCSA]		ationship of Reporting Person(s) to Issuer k all applicable) Director 10% Owner					
(Last)	Last) (First) (Middle) C/O PROCESSA PHARMACEUTICALS, INC.		 3. Date of Earliest Transaction (Month/Day/Year) 06/27/2023 		Officer (give title below)	Other (specify below)				
C/O PROCESSA PHARMACEUTICALS, INC. 7380 COCA COLA DRIVE, SUITE 106			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indivi	6. Individual or Joint/Group Filing (Check Applicable Line)					
		UITE 100		X	Form filed by One Reporting Person					
(Street)					Form filed by More that	n One Reporting Person				
HANOVER	MD	21076								
(City)	(State)	(Zip)	—							
		Table I - Non-D	Perivative Securities Acquired, Disposed of, or Benefi	cially Owr	ned					

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			Securities Beneficially Owned Following Reported	Form: Direct (D)	Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	06/27/2023		М		15,455	A	(1)	27,955	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (In 8)		5. Number Derivative Securities Acquired Disposed (Instr. 3, 4	e s (A) or l of (D)	6. Date Exerc Expiration D (Month/Day/\	ate	Securities Un	ecurities Underlying erivative Security (Instr.		9. Number of derivative Securities Beneficially Owned Following	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Reported Transaction(s) (Instr. 4)		
Restricted Stock	\$ 0	06/27/2023		М			15,455	(1)	(1)	Common Stock	15,455	\$0	0	D	
Restricted Stock	\$ <u>0</u>	06/27/2023		Α		101,365		(2)	(2)	Common Stock	101,365	\$0	101,365	D	

Explanation of Responses:

1. Vesting of time-based restricted shares.

2. The restricted stock vests on the earliest of one year from date of grant or the next annual meeting of stockholders.

as Attorney-in-fact	/s/ Khoso Baluch by Neda Sharifi.	07/24/2022
	as Attorney-in-fact	0//24/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.